EXPERIMENTICA OY

Their core work

Experimentica is a Finnish contract research organization (CRO) specializing in preclinical ophthalmic pharmacology. They design and run in vitro, ex vivo, and in vivo models to test drug delivery systems, pharmaceutical formulations, and medical devices targeting diseases of the posterior eye segment — conditions like age-related macular degeneration, diabetic retinopathy, and glaucoma. As an industry partner in EU training and exchange consortia, they provide the experimental infrastructure and applied expertise that academic teams typically lack: validated ocular models, bioanalytical assays, and hands-on testing of candidate therapeutics. More recently their scope has extended to cysteinyl leukotriene signaling pathways relevant to both ocular and central nervous system dysfunction, suggesting capacity in broader neuroinflammatory research.

What they specialise in

How they've shifted over time

Experimentica entered H2020 through ORBITAL (2019) with a tightly focused profile: preclinical models, ocular drug delivery, formulations, and medical devices for posterior segment diseases — essentially the core service offering of an ophthalmic CRO. By 2021, CRYSTAL3 introduced a meaningful expansion: the project targets leukotriene-driven inflammation at the intersection of ocular and CNS pathology, which goes beyond classical ophthalmology into neuroinflammation and brain-eye axis research. With only two projects the shift is a signal, not a pattern, but it suggests the organization is following the growing scientific interest in shared inflammatory mechanisms between the eye and the brain.

Experimentica appears to be moving from pure ophthalmic CRO services toward broader neuroinflammatory research, positioning at the eye–brain interface — a growing area for pharma companies developing dual-indication therapies.

How they like to work

Experimentica has participated in two projects and coordinated none, which is typical of specialist CROs embedded in academic-led training networks (MSCA-ITN) and researcher exchange programmes (MSCA-RISE). Their role is to provide industrial context and experimental capacity rather than to drive scientific strategy. With 33 unique partners across 12 countries from only two projects, they operate in large, multi-node consortia — the MSCA model by design — rather than in small bilateral collaborations.

Despite only two projects, Experimentica has built connections with 33 partners in 12 countries, reflecting the broad consortium structures of MSCA networks. Their network is European in scope with no data suggesting a particular regional cluster beyond Finland as home base.

What sets them apart

Experimentica is one of very few SMEs in Finland operating as a dedicated ophthalmic CRO with full-spectrum preclinical model capability — from cell-based assays to animal models — for posterior segment eye diseases. Their participation in MSCA networks signals academic credibility alongside commercial CRO services, which is a combination that appeals to pharma partners who need both regulatory-grade data and publication-ready science. The emerging CNS angle adds a differentiating dimension that pure ophthalmology CROs cannot easily match.

Highlights from their portfolio

• ORBITAL
  Largest funded project (EUR 280,806 to Experimentica alone) and the most keyword-rich, establishing the organization's core identity as an ophthalmic drug delivery and modeling specialist within a pan-European training network.
• CRYSTAL3
  Signals a strategic expansion beyond classical ophthalmology into CNS dysfunction via cysteinyl leukotriene signaling — a disease mechanism of interest to neuroinflammation and rare-disease drug developers.